Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

Summary

This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.

Timeline

Start

2026-02-02

Primary completion

2027-02-14

Completion

2028-02-17

Drugs

Indications